GlassScriptPhysician profile
Neema Navai
NPI 1952572216
$9,484.50
in general payments reported to CMS, 2019-2025
8 companies · $8,997 in 2025
The $8,997 reported for 2025 was more than what 93% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.98 · 2020: $152 · 2023: $135 · 2024: $136 · 2025: $8,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,690 · Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,690.00 |
| Food and Beverage | $578.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $5,360.59 | 2025 | Adstiladrin |
| Pfizer INC. | $3,465.00 | 2025 | |
| Boston Scientific Corporation | $171.43 | 2025 | Ams 800 Artificial Urinary Sphincter |
| Astellas Pharma US INC | $152.19 | 2020 | |
| Janssen Scientific Affairs, LLC | $136.08 | 2024 | |
| Janssen Biotech, INC. | $135.23 | 2023 | Balversa, Erleada |
| Intuitive Surgical, INC. | $63.98 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neema Navai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.